Vascular endothelial growth factor

Where the papers sit

22 papers from the last 6 months study vascular endothelial growth factor directly · updated from PubMed 1 Nov 2026

• Engineered Angiogenesis for Repair

  Controlled VEGF delivery is moving toward biomimetic repair platforms that combine VEGF with FGF-2, PDGF, stem cells, melatonin or cardiac-regenerative agents. GelMA and other hydrogels, plasmid or self-amplifying RNA delivery, and affinity control aim to produce stable vascular networks rather than transient sprouting. Nerve, heart and fibrotic-lung studies show that vessel function, lymphatic drainage and pathological remodeling remain important constraints.

  7 papers · 31.8%

• Anti-VEGF Clinical Translation

  Anti-VEGF treatment is being refined through real-world follow-up, safety monitoring and adjunctive ocular care, especially for macular disease. Aflibercept 8 mg and tear substitutes address durability and surface toxicity after repeated intravitreal therapy. Oncology studies pair VEGF blockade with nivolumab or use imaging and survival endpoints to guide selection. Applications remain divided between retinal management and experimental cancer therapy.

  6 papers · 27.3%

• Diabetic Retinopathy Angiogenesis

  Diabetic retinopathy research is moving beyond VEGF alone toward inflammatory and neurovascular mechanisms that govern retinal angiogenesis. Galectin-3 and NET-mediated microglia–neutrophil signaling, along with microglial exosomal miR-31-5p, emerge as targets that disrupt vascular homeostasis. Danegaptide is being evaluated from preclinical work into clinical treatment of nonproliferative disease. The central challenge is suppressing pathological growth without impairing physiological repair.

  3 papers · 13.6%

• Others — Angiogenesis Across Disease Contexts

  Regenerative studies use VEGF-linked angiogenesis to improve diabetic wounds, burns, bone healing and scarless repair, often with hydrogels, nanoparticles or mechanical stimulation. Cancer-focused work instead tests VEGF neutralization and immune biomarkers. Collagen deposition, CD31-positive vessels and VEGF/VEGFR2 signaling recur as repair endpoints, but the mixed indications support no single therapeutic direction.

  6 papers · 27.3%